Catalog No.
Product Name
Application
Product Information
Citations
- (+)-Clopidogrel hydrogen sulfate is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
-
platelet inhibitor
Prasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. -
P2Y12 antagonist
Ticagrelor (AZD6140) is the first reversibly binding oral P2Y(12) receptor antagonist that blocks ADP-induced platelet aggregation. - Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist
- Tasuku SAKAYORI, .et al. , Sysmex Journal International, 2024, Vol.34 No.1
- Satoru Koyanagi, .et al. , Nat Commun, 2016, 7: 13102 PMID: 27739425
- Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
- Methylthioadenosine is a naturally occurring sulfur-containing nucleoside present in all mammalian tissues.
-
P2Y12 antagonist
Prasugrel is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events. -
P2Y12 receptors inhibitor
Cangrelor Tetrasodium is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion. -
P2Y12 receptor inhibitor
Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent. -
P2Y Receptor Inhibitor
N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). -
P2Y12 receptor inhibitor
Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. -
P2Y12 receptor antagonist
Prasugrel (PCR 4099) Maleic acid is a platelet inhibitor with IC50 value of 1.8 μM. -
P2Y6 Receptor Agonist
PSB 0474 (3-phenacyl-UDP) is a selective and potent agonist of the P2Y6 receptor, exhibiting an EC50 of 70 nM. This compound modulates key biological activities, including the inhibition of cell proliferation and the enhancement of nitric oxide release in astrocytes and microglia. Additionally, PSB 0474 promotes apoptosis in astrocytes, making it a valuable tool for research in neurobiology and cell signaling pathways. -
P2Y6 Agonist
MRS2693 ammonium is a selective agonist targeting the P2Y6 receptor, exhibiting an EC50 of 0.015 μM. This compound demonstrates significant biological activity by protecting C2C12 skeletal muscle cells from TNFα-induced apoptosis and reducing NF-kB activation. Additionally, MRS2693 ammonium activates the ERK1/2 signaling pathway and has shown cytoprotective effects in a mouse model of ischemia-reperfusion injury, making it a valuable tool for research in cellular protection and signaling pathways. -
P2Y2 Agonist
Diquafosol is a potent P2Y2 receptor agonist that plays a significant role in modulating cellular responses associated with inflammation and apoptosis. It exhibits the ability to inhibit apoptotic pathways and reduce reactive oxygen species (ROS) generation, thereby promoting cell survival. Diquafosol is primarily used in research related to dry eye therapies, providing valuable insights into potential treatment strategies for this condition. -
P2Y14R Antagonist
P2Y14R Antagonist 1 is a highly selective antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.6 nM. It demonstrates significant antagonistic activity against P2Y14R, with both in vitro and in vivo efficacy, along with favorable pharmacokinetic properties. This compound effectively reduces the release of inflammatory mediators and mitigates cell pyroptosis through the NLRP3/Gasdermin D signaling pathway. P2Y14R Antagonist 1 is a valuable tool for research investigating acute gouty arthritis and related inflammatory conditions. -
P2Y Receptor Modulator
Uridine-5'-diphosphate disodium salt functions as an agonist for the P2Y6 receptor, exhibiting high specificity with an EC50 of 300 nM (pEC50=6.52 for the human P2Y6 receptor). This endogenous metabolite plays a crucial role in catalyzing the glucuronidation of various substrates and is also instrumental in RNA biosynthesis. Its modulation of P2Y receptors has significant implications for research in cellular signaling and metabolic processes. -
P2Y Receptor Modulator
Uridine 5'-diphosphate sodium salt is a specific modulator of P2Y receptors, acting as a potent native agonist for the P2Y6 receptor with an EC50 of 300 nM and a pEC50 of 6.52, while also serving as a powerful antagonist at the P2Y14 receptor (pEC50 of 7.28). This endogenous metabolite plays a crucial role in the glucuronidation process of diverse substrates and is integral to nucleic acid biosynthesis, making it a valuable reagent in biochemical and pharmacological research focused on nucleotide signaling pathways and metabolic processes. -
P2Y14R Inhibitor
HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. This compound effectively blocks the activation of hepatic stellate cells by inhibiting the PKA/Raf1/MEK/ERK signaling pathway associated with P2Y14R, thereby mitigating the progression of liver fibrosis. HDB-1 is valuable for research into the mechanisms underlying liver fibrosis and the development of potential therapeutic strategies. -
P2Y6 Agonist
MRS2693 trisodium is a selective agonist of the P2Y6 receptor, exhibiting an EC50 value of 0.015 μM. It significantly reduces NF-kappaB activation while activating the ERK1/2 signaling pathway. MRS2693 trisodium demonstrates cytoprotective effects in models of ischemia-reperfusion injury in mouse hindlimb skeletal muscle, making it a valuable tool for research in cellular signaling and tissue injury responses. -
P2Y14R Antagonist
P2Y14R Antagonist 4 is a potent oral antagonist of the P2Y14 receptor, exhibiting an IC50 value of 5.6 nM, indicating high binding affinity. This compound demonstrates anti-inflammatory activity by effectively reducing the release of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in response to LPS stimulation. P2Y14R Antagonist 4 is valuable for research applications in inflammation and immune response modulation. -
P2Y14 Receptor Agonist
MRS2690 is a selective agonist of the P2Y14 receptor, primarily known for its role in the inhibition of adenylyl cyclase activity, which leads to a reduction in intracellular cAMP levels. This compound mediates concentration-dependent vasoconstriction in porcine coronary arteries and induces intracellular calcium mobilization. Additionally, MRS2690 activates p38 MAPK and stimulates [35S]GTPγS binding in RBL-2H3 cell membranes. It also enhances β-hexosaminidase release in response to antigen and complement activation, making it a valuable tool for research in ischemic heart disease. -
P2Y11 Receptor Agonist
ATPγS tetralithium salt is a highly effective agonist of the P2Y11 receptor, playing a pivotal role in various cellular signaling pathways. This compound exhibits notable antioxidant properties and provides neuroprotection, enhancing its utility in neuroscience research. Additionally, ATPγS serves as a substrate for nucleotide hydrolysis and RNA unwinding activities mediated by the eukaryotic translation initiation factor eIF4A, making it valuable for studies related to translation and RNA biology. Its activity in ATP hydrolysis further supports its application in metabolic research. -
P2Y11 Receptor Agonist
ATP-γ-S tetrasodium is a potent agonist of the P2Y11 receptor, known for its antioxidant and neuroprotective properties. This compound serves as a substrate for nucleotide hydrolysis and facilitates RNA unwinding activities of the eukaryotic translation initiation factor eIF4A. Additionally, ATP-γ-S tetrasodium demonstrates significant activity in ATP hydrolysis, making it valuable for studies in cellular signaling and translational control. -
P2Y14R Antagonist
HDL-16 is a highly potent antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.3095 nM. This compound demonstrates significant biological activity by alleviating dextran sulfate sodium (DSS)-induced colitis, primarily through the inhibition of necroptosis in intestinal epithelial cells (IECs) and the preservation of mucosal barrier function. HDL-16 is valuable for research applications focused on inflammatory bowel diseases and related gastrointestinal disorders. -
P2Y1 receptor/[35S]GTPγS binding/β-arrestin 2 recruitment Agonist
MRS2365 is a highly potent and selective agonist of the P2Y1 receptor, exhibiting an EC50 of 0.4 nM for [35S]GTPγS binding and β-arrestin 2 recruitment. This compound effectively alleviates mechanical allodynia and enhances mechanical sensitivity, making it valuable for pain research. Notably, MRS2365 demonstrates minimal activity at P2Y12 and P2Y13 receptors, highlighting its specificity for P2Y1. -
P2Y14R Antagonist
MK-852 is a potent P2Y14 receptor antagonist that plays a crucial role in modulating platelet aggregation. This compound effectively inhibits the binding of fibrinogen to platelets in vitro, making it a valuable tool for studying thrombotic processes. Research applications include investigations into platelet function and the development of antithrombotic therapies. -
P2Y14 Agonist
Uridine 5'-diphosphoglucose disodium is a potent agonist of the P2Y14 receptor, which plays a critical role in the regulation of inflammation and neutrophil polarization in response to ischemic conditions. Secreted by cardiomyocytes, this compound is involved in the synthesis of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in various biological systems. Its ability to modulate inflammatory responses makes Uridine 5'-diphosphoglucose disodium a valuable reagent for studies focused on myocardial infarction and reperfusion-induced inflammation. -
P2Y14R Antagonist
MRS4654 is a potent antagonist of the P2Y14 receptor, with reported inhibitory constants of 15.0 nM for human P2Y14 and 18.6 nM for mouse P2Y14. This compound exhibits significant analgesic and anti-inflammatory properties, making it a valuable tool for investigating pathways involved in pain modulation. MRS4654 is suitable for research applications focused on asthma and neuropathic pain models. -
P2Y14 Receptor Agonist
UDP-Galactose disodium is a potent agonist of the P2Y14 receptor, demonstrating an EC50 of 0.67 μM for the human variant. This compound serves as a substrate for the enzyme beta-1,4 galactosyltransferase V (B4GALT5), playing a critical role in glycosylation processes. Additionally, UDP-Galactose disodium is essential for the biosynthesis of various glycoconjugates that contribute to the surface glycocalyx of Leishmania major, making it valuable for research in cell signaling and pathogen biology. -
P2Y2 Receptor Antagonist
AR-C118925XX is a selective antagonist of the P2Y2 receptor. It effectively inhibits ATP-induced production of interleukin-6 (IL-6) and the phosphorylation of p38 MAPK, key players in inflammatory responses. In vivo studies demonstrate that AR-C118925XX also suppresses Bleomycin-induced dermal fibrosis in mice and inhibits ATP-mediated tumor growth, making it valuable for research in fibrosis, inflammation, and cancer biology. -
P2Y12 Receptor Antagonist
PSB-0739 is a potent, high-affinity competitive antagonist of the P2Y12 receptor, exhibiting a Ki value of 24.9 nM. This receptor is essential for platelet aggregation, and its inhibition may provide valuable insights into antithrombotic therapies. PSB-0739 is suitable for research applications focused on cardiovascular disease and platelet function studies. -
P2Y Receptor Agonist
2-Methylthioadenosine diphosphate trisodium is a potent agonist of purinergic P2Y receptors, specifically exhibiting EC50 values of 19 nM, 6.2 nM, and 5 nM for human P2Y13, mouse P2Y13, and human P2Y12, respectively. Additionally, it demonstrates pEC50 values of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. This compound is known to induce platelet aggregation and morphological changes while inhibiting cyclic AMP accumulation in platelets in the presence of prostaglandin E1, making it a valuable tool for research in platelet function and signaling pathways. -
P2Y14-R Antagonist
PPTN hydrochloride is a selective P2Y14 receptor antagonist characterized by a high-affinity competitive binding with a KB value of 434 pM. This compound exhibits significant anti-inflammatory and anti-immune properties, making it a valuable tool in research related to autoimmune diseases and inflammation pathways. Additionally, PPTN hydrochloride demonstrates no agonist or antagonist effects on other P2Y receptor subtypes, including P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13, ensuring its specificity in biological assays. -
P2Y14-R Antagonist
PPTN is a potent, high-affinity antagonist of the P2Y14 receptor, exhibiting a competitive binding profile with a KB value of 434 pM. This compound demonstrates selectivity by showing no significant agonist or antagonist effects on other P2Y receptors, including P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13. PPTN is useful for research applications focused on anti-inflammatory and immune modulation, providing a valuable tool for studying P2Y14-mediated biological processes. -
P2Y11 Antagonist
NF157 is a selective antagonist of the P2Y11 receptor, exhibiting a pKi of 7.35 and an IC50 of 463 nM. It demonstrates high specificity, with significantly higher IC50 values for related receptors P2Y1 and P2Y2. NF157 is known to reduce the expression of metalloproteinases (MMP)-3 and MMP-13, making it a valuable tool for research into osteoarthritis and related inflammatory conditions. -
P2Y12 Receptor Activator
ADP-β-S trilithium is the trilithium salt form of ADP-β-S, serving as a potent activator of the P2Y12 receptor. It facilitates the upregulation of IL-1β and IL-6 production in microglial cells, promotes NF-κB phosphorylation and nuclear translocation, and enhances NLRP3 inflammasome activation. This reagent is valuable for research into inflammatory responses and signaling pathways involving P2Y12 receptor activation. -
P2Y2R/GPR17 Antagonist
P2Y2R/GPR17 antagonist 1 is a selective antagonist targeting both the P2Y2 receptor (P2Y2R) and G protein-coupled receptor 17 (GPR17), with IC50 values of 3.17 µM and 1.67 µM, respectively. This compound exhibits promising metabolic stability in human liver microsomes, making it a valuable tool for research. It is particularly applicable in studies involving purinergic signaling and neuroinflammation, providing insights into therapeutic strategies for related diseases. -
P2Y13 Receptor Antagonist
MRS 2211 sodium hydrate is a competitive antagonist of the P2Y13 receptor, exhibiting a pIC50 of 5.97. It demonstrates over 20-fold selectivity for the P2Y13 receptor compared to the P2Y1 and P2Y12 receptors. This selective antagonist is valuable for investigating the role of the P2Y13 receptor in various physiological and pathological processes, including its effects in blood cells, the nervous system, and the immune system. -
P2Y1 Receptor Antagonist
MRS2500 tetraammonium is a highly selective antagonist of the P2Y1 receptor, exhibiting a Ki value of 0.78 nM for the recombinant human P2Y1 receptor. This compound effectively inhibits ADP-induced aggregation of human platelets, demonstrating an IC50 of 0.95 nM. MRS2500 tetraammonium is utilized in research applications focused on antithrombotic activity and the modulation of platelet function. -
P2Y12 Antagonist
2-Methylthio-AMP (2-MeSAMP) is a selective antagonist of the P2Y12 receptor, which plays a critical role in mediating platelet aggregation through ADP signaling. This compound effectively inhibits ADP-induced platelet activation, making it a valuable tool for studying platelet function and thrombosis. Its application extends to cardiovascular research, where it can help elucidate the mechanisms underlying platelet aggregation and potential therapeutic strategies for related disorders. -
P2Y1 Receptor Antagonist
PIT (2,2'-Pyridylisatogen tosylate) is a selective non-competitive antagonist of the P2Y1 receptor, exhibiting an IC50 value of 0.14 μM for human P2Y1 receptors. It effectively inhibits P2Y1 receptor signaling without interfering with nucleotide binding, demonstrating irreversible antagonism of ATP responses at metabotropic purinoceptors within certain smooth muscle tissues. PIT is valuable for investigating conditions such as chronic bronchitis and asthma, facilitating research into the role of purinergic signaling in these respiratory disorders. -
P2Y14R Antagonist
P2Y14R Antagonist 2 is a potent and selective antagonist of the P2Y14 receptor, demonstrating an IC50 of 0.40 nM. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research related to colitis and other inflammatory conditions. Its oral bioavailability enhances its applicability in various preclinical studies. -
P2Y2 Receptor Agonist
4-Thiouridine 5′-triphosphate tetralithium is a potent agonist for the P2Y2 and P2Y4 receptors, demonstrating EC50 values of 35 nM and 350 nM, respectively. This UTP analog is utilized in various research applications, including cross-linking experiments and transcriptional complex labeling studies, making it an essential tool for investigating nucleic acid interactions and cell signaling pathways.
